Catalyst Biosciences Announces Poster Presentations at the EAHAD 2021 Virtual Congress
Catalyst Biosciences (NASDAQ: CBIO) announced two e-poster presentations at the EAHAD Virtual Congress occurring from February 3-5, 2021. The posters highlight the effectiveness of Marzeptacog Alfa (Activated) for treating spontaneous bleeding in both hemophilia A rats and dogs. Presenters include Tom Knudsen and Howard Levy, with accessible materials post-event on the Catalyst website.
Additionally, Catalyst is focused on developing solutions for rare coagulation disorders and has a partnership with Biogen for complement-related therapies.
- Two e-posters presented at the EAHAD Virtual Congress emphasize the efficacy of Marzeptacog Alfa for bleeding disorders.
- Strong focus on unmet medical needs in rare disorders enhances the company's market position.
- Potential for trial delays or unsatisfactory outcomes due to COVID-19 and other factors.
- Risks associated with MarzAA, including possible generation of neutralizing antibodies.
- Increased development costs could impact financial performance.
SOUTH SAN FRANCISCO, Calif., Jan. 20, 2021 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO), today announced two e-poster presentations at the European Association for Haemophilia and Allied Disorders (EAHAD) Virtual Congress being held on February 3 - 5, 2021.
| Poster presentation details | ||
| Poster Title: | Subcutaneous Marzeptacog Alfa (Activated) is effective for on-demand treatment of spontaneous bleeding in hemophilia A rats | |
| Presenter: | Tom Knudsen, DVM, Ph.D., vice president of translational research, Catalyst Biosciences | |
| Program number: | ABS027 | |
| Date/Time: | Poster available starting at 6 pm CET on February 2, through August 5, 2021 | |
| Poster Title: | Subcutaneous Marzeptacog Alfa (Activated) is effective for on-demand treatment of spontaneous bleeding in dogs with Hemophilia A | |
| Presenter: | Howard Levy, M.B.B.Ch., Ph.D., M.M.M., chief medical officer, Catalyst Biosciences | |
| Program number: | ABS028 | |
| Date/Time: | Poster available starting at 6 pm CET on February 2, through August 5, 2021 | |
A copy of the presentation materials can be accessed on the Events and Presentations section of the Catalyst website (www.catalystbiosciences.com) once the presentations conclude.
About Catalyst Biosciences, the Protease Medicines company
Catalyst is a research and clinical development biopharmaceutical company focused on addressing unmet medical needs in rare disorders of the complement and coagulation systems. Our protease engineering platform has generated two late-stage clinical programs, including MarzAA, a subcutaneously (SQ) administered next-generation engineered coagulation Factor VIIa (FVIIa) for the treatment of episodic bleeding in subjects with rare bleeding disorders. Our complement pipeline includes a pre-clinical program partnered with Biogen for dry age-related macular degeneration, an improved complement factor I protease for SQ replacement therapy in patients with CFI deficiency and C4b-degraders designed to target disorders of the classical complement pathway as well as other complement programs in development.
Forward-Looking Statements
This press release contains forward-looking statements that involve substantial risks and uncertainties. Forward-looking statements include statements about Catalyst’s product candidates and the benefits of its protease engineering platform. Actual results or events could differ materially from the plans, intentions, expectations and projections disclosed in the forward-looking statements. Various important factors could cause actual results or events to differ materially, including, but not limited to, the risk that trials and studies may be delayed as a result of COVID-19 and other factors, that trials may not have satisfactory outcomes, that additional human trials will not replicate the results from earlier trials, that potential adverse effects may arise from the testing or use of MarzAA, including the generation of neutralizing antibodies, the risk that costs required to develop or manufacture the Company’s products will be higher than anticipated, including as a result of delays in trial enrollment, development and manufacturing resulting from COVID-19 and other factors, the risk that Biogen will terminate Catalyst’s agreement, competition and other risks described in the “Risk Factors” section of the Company’s quarterly report filed with the Securities and Exchange Commission on November 5, 2020, and in other filings with the Securities and Exchange Commission. The Company does not assume any obligation to update any forward-looking statements, except as required by law.
Contact:
Ana Kapor
Catalyst Biosciences, Inc.
investors@catbio.com
FAQ
What are the details of Catalyst Biosciences' e-poster presentations at EAHAD 2021?
When is the EAHAD Virtual Congress taking place?
Who are the presenters for the Catalyst Biosciences posters?
What is Marzeptacog Alfa?
How does Catalyst Biosciences address rare disorders?
